AQSTAquestive Therapeutics, Inc.

Revenue grew 38% year-over-year to $13.8 million as Anaphylm resubmission nears.

Company advances toward Q3 NDA resubmission with improved human factors data, while total revenue climbs to $13.8 million and adjusted EBITDA loss narrows to $5.2 million.

Aquestive Therapeutics (NASDAQ:AQST) said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis, before the end of the third quarter after completing studies requested by the U.S. Food and Drug Admini

Moby summary of Aquestive Therapeutics, Inc.'s Q2 2026 earnings call

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -80.00% and +12.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (NASDAQ:AQST) shares rose 9. 5% on Monday after the pharmaceutical company reported positive human factors and pharmacokinetic study results for Anaphylm, strengthening its preparations to resubmit a New Drug Application to the U.

Aquestive Therapeutics' (AQST) Anaphylm sublingual film, a potential treatment for life-threatening

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.